{"id":380845,"date":"2020-11-13T09:03:27","date_gmt":"2020-11-13T14:03:27","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380845"},"modified":"2020-11-13T09:03:27","modified_gmt":"2020-11-13T14:03:27","slug":"enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/","title":{"rendered":"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">VANCOUVER, British Columbia, Nov.  13, 2020  (GLOBE NEWSWIRE) &#8212; <strong>EnWave Corporation (TSX-V:ENW | FSE:E4U) (\u201cEnWave\u201d, or the \u201cCompany\u201d)<\/strong>\u00a0announced today that it has signed an Equipment Purchase Agreement (the \u201cAgreement\u201d) with GEA Lyophil GmbH (\u201cGEA\u201d) to deliver a lab-scale Radiant Energy Vacuum (\u201cREV\u2122\u201d) machine for the demonstration and development of REV\u2122 technology for pharmaceutical applications.<\/p>\n<p align=\"justify\">GEA will use the equipment to advance the commercialization of the technology for pharmaceutical applications. The lab-scale machine will be made available for trials with prospective pharma-industry purchasers of large-scale microwave-assisted lyophilization equipment. This machine will also be used for internal evaluation and technology advancement activities at GEA. This will allow GEA to better showcase EnWave\u2019s technology to pharmaceutical companies as a first step in evaluating the merits of adopting larger-scale capacity.<\/p>\n<p align=\"justify\">GEA intends to install the customized lab-scale REV\u2122 machine at its pilot facility in H\u00fcrth, Germany<\/p>\n<p align=\"justify\">In January 2020, EnWave and GEA announced a Joint Development Agreement, where the companies agreed to work closely to combine GEA\u2019s leading pharmaceutical industry manufacturing capabilities with EnWave\u2019s patented microwave-assisted lyophilization technology. GEA is a global leader in the design, manufacture, and installation of GMP equipment to the pharmaceutical sector, and is working with EnWave to incorporate REV\u2122 technology into its suite of products. EnWave\u2019s pharmaceutical technology allows for a rapid and controlled drying process for sensitive vaccines and biological compounds.<\/p>\n<p align=\"justify\">Under the terms of the Joint Development Agreement, GEA will be responsible for the design, manufacture and sale of any large-scale REV\u2122 equipment sold to the pharmaceutical sector, and EnWave shall earn an undisclosed royalty based on the revenue generated.<\/p>\n<p align=\"justify\">\n        <strong>About <\/strong><br \/>\n        <strong>GEA Lyophil GmbH <\/strong><br \/>\n        <br \/>GEA Lyophil GmbH is part of the GEA group of companies. GEA is one of the largest technology suppliers for food and pharmaceutical processing, and a wide range of other industries. The global group specializes in machinery, plants, as well as process technology and components. GEA provides sustainable solutions for sophisticated production processes in diverse end-user markets and offers a comprehensive service portfolio.<\/p>\n<p align=\"justify\">For more information about GEA, please visit <a href=\"http:\/\/www.gea.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.gea.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About EnWave<\/strong><br \/>\n        <br \/>EnWave Corporation, a Vancouver-based advanced technology company, has developed a Radiant Energy Vacuum (\u201cREV\u2122\u201d) \u2013 an innovative, proprietary method for the precise dehydration of organic materials. EnWave has further developed patent-pending methods for uniformly drying and decontaminating cannabis through the use of REV\u2122 technology, shortening the time from harvest to marketable cannabis products.<\/p>\n<p align=\"justify\">REV\u2122 technology\u2019s commercial viability has been demonstrated and is growing rapidly across several market verticals in the food, and pharmaceutical sectors, including legal cannabis. EnWave\u2019s strategy is to sign royalty-bearing commercial licenses with innovative, disruptive companies in multiple verticals for the use of REV\u2122 technology. The company has signed over thirty royalty-bearing licenses to date. In addition to these licenses, EnWave established a Limited Liability Corporation, NutraDried Food Company, LLC, to manufacture, market and sell all-natural dairy snack products in the United States, including the Moon Cheese<sup>\u00ae<\/sup> brand.<\/p>\n<p align=\"justify\">EnWave has introduced REV\u2122 as a disruptive dehydration platform in the food and cannabis sectors: faster and cheaper than freeze drying, with better end product quality than air drying or spray drying. EnWave currently offers two distinct commercial REV\u2122 platforms:<\/p>\n<ol style=\"list-style-type:decimal\">\n<li style=\"margin-bottom:10pt\">\n          <em>nutra<\/em>REV<sup>\u00ae<\/sup> which is a drum-based system that dehydrates organic materials quickly and at low-cost, while maintaining high levels of nutrition, taste, texture and colour; and,<\/li>\n<li style=\"margin-bottom:10pt\">\n          <em>quanta<\/em>REV<sup>\u00ae<\/sup> which is a tray-based system used for continuous, high-volume low-temperature drying.<\/li>\n<\/ol>\n<p>More information about EnWave is available at <a href=\"http:\/\/www.enwave.net\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.enwave.net<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>EnWave Corporation<\/strong><br \/>\n        <br \/>Mr. Brent Charleton, CFA<br \/>President and CEO<\/p>\n<p>For further information:<br \/>Brent Charleton, CFA, President and CEO at +1 (778) 378-9616<br \/>E-mail: <a href=\"mailto:bcharleton@enwave.net\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">bcharleton@enwave.net<\/a> \u00a0\u00a0 \u00a0\u00a0\u00a0 <\/p>\n<p>Dan Henriques, CPA, CA, CFO at +1 (604) 835-5212<br \/>E-mail: <a href=\"mailto:dhenriques@enwave.net\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">dhenriques@enwave.net<\/a><\/p>\n<p align=\"justify\">\n        <em>Safe Harbour for Forward-Looking Information Statements: This press release may contain forward-looking information based on management&#8217;s expec<\/em><br \/>\n        <em>tations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company&#8217;s strategy for growth, product development, market position, expected expenditures, and the expected synergies following the closing are forward-looking statements. All <\/em><br \/>\n        <em>third-party<\/em><br \/>\n        <em> claims referred to in this release ar<\/em><br \/>\n        <em>e not guaranteed to be accurate. All <\/em><br \/>\n        <em>third-party<\/em><br \/>\n        <em> references to market information in this release are not guaranteed to be accurate as the Company did not conduct the original primary research. These statements<\/em><br \/>\n        <em> are not a guarantee of future performance and involve a number of risks, uncertainties and assumptions. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.<\/em>\n      <\/p>\n<p align=\"center\">\n        <strong>Neither the TSX Venture Exchange nor it<\/strong><br \/>\n        <strong>s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/strong>\n      <\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; EnWave Corporation (TSX-V:ENW | FSE:E4U) (\u201cEnWave\u201d, or the \u201cCompany\u201d)\u00a0announced today that it has signed an Equipment Purchase Agreement (the \u201cAgreement\u201d) with GEA Lyophil GmbH (\u201cGEA\u201d) to deliver a lab-scale Radiant Energy Vacuum (\u201cREV\u2122\u201d) machine for the demonstration and development of REV\u2122 technology for pharmaceutical applications. GEA will use the equipment to advance the commercialization of the technology for pharmaceutical applications. The lab-scale machine will be made available for trials with prospective pharma-industry purchasers of large-scale microwave-assisted lyophilization equipment. This machine will also be used for internal evaluation and technology advancement activities at GEA. This will allow GEA to better showcase EnWave\u2019s technology to pharmaceutical companies as a first step in evaluating &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380845","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; EnWave Corporation (TSX-V:ENW | FSE:E4U) (\u201cEnWave\u201d, or the \u201cCompany\u201d)\u00a0announced today that it has signed an Equipment Purchase Agreement (the \u201cAgreement\u201d) with GEA Lyophil GmbH (\u201cGEA\u201d) to deliver a lab-scale Radiant Energy Vacuum (\u201cREV\u2122\u201d) machine for the demonstration and development of REV\u2122 technology for pharmaceutical applications. GEA will use the equipment to advance the commercialization of the technology for pharmaceutical applications. The lab-scale machine will be made available for trials with prospective pharma-industry purchasers of large-scale microwave-assisted lyophilization equipment. This machine will also be used for internal evaluation and technology advancement activities at GEA. This will allow GEA to better showcase EnWave\u2019s technology to pharmaceutical companies as a first step in evaluating &hellip; Continue reading &quot;EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T14:03:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development\",\"datePublished\":\"2020-11-13T14:03:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/\"},\"wordCount\":842,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/\",\"name\":\"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY=\",\"datePublished\":\"2020-11-13T14:03:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/","og_locale":"en_US","og_type":"article","og_title":"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development - Market Newsdesk","og_description":"VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; EnWave Corporation (TSX-V:ENW | FSE:E4U) (\u201cEnWave\u201d, or the \u201cCompany\u201d)\u00a0announced today that it has signed an Equipment Purchase Agreement (the \u201cAgreement\u201d) with GEA Lyophil GmbH (\u201cGEA\u201d) to deliver a lab-scale Radiant Energy Vacuum (\u201cREV\u2122\u201d) machine for the demonstration and development of REV\u2122 technology for pharmaceutical applications. GEA will use the equipment to advance the commercialization of the technology for pharmaceutical applications. The lab-scale machine will be made available for trials with prospective pharma-industry purchasers of large-scale microwave-assisted lyophilization equipment. This machine will also be used for internal evaluation and technology advancement activities at GEA. This will allow GEA to better showcase EnWave\u2019s technology to pharmaceutical companies as a first step in evaluating &hellip; Continue reading \"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T14:03:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development","datePublished":"2020-11-13T14:03:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/"},"wordCount":842,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/","name":"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY=","datePublished":"2020-11-13T14:03:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTEzMSMzODI0NjYxIzIwMDk2ODY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enwave-signs-equipment-purchase-agreement-gea-lyophil-gmbh-and-advances-joint-pharmaceutical-technology-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"EnWave Signs Equipment Purchase Agreement GEA Lyophil GmbH and Advances Joint Pharmaceutical Technology Development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380845"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380845\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}